Combination of daclizumab and vaccine improves survival of breast cancer patients

[News]

A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab.

More... (http://www.news-medical.net/news/20120517/Combination-of-daclizumab-and-vaccine-improves-survival-of-breast-cancer-patients.aspx)